Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 4:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 1,358 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: FAST alone Clear all
Not listed Not applicable Interventional

End-Tidal Oxygen for Intubation in the Emergency Department

NCT06578468
View directory record Official record
Conditions
Critical Illness, Hypoxia, Respiratory Failure
Interventions
End-tidal oxygen monitor
Device
Lead sponsor
Sydney Local Health District
Government
Eligibility
18 Years and older
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Minneapolis, Minnesota • Albuquerque, New Mexico • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 27, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of the Pharmacokinetic Variability and Relative Bioavailability of the Phase 3 and Common Blend Formulations of Eliglustat in Healthy Adult Subjects

NCT01452542
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Eliglustat, common blend proposed commercial formulation, Eliglustat, Phase 3 capsule formulation
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Oct 27, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Isotretinoin Capsules 20 mg Under Fasting Condition

NCT01888341
View directory record Official record
Conditions
Healthy
Interventions
Isotretinoin
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Quadrangle Drive, Chapel Hill,, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 27, 2013 · Synced Oct 27, 2026, 4:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Perceptions of and Reactions to Ultra-Processed Menu Label Designs

NCT07214805
View directory record Official record
Conditions
Food Choices
Interventions
Ultra-Processed, Red, Icon-plus-text Labels, Contains Food Additives, Red, Icon-plus-text Labels, Warning Ultra-Processed, Red, Icon-plus-text Labels, Warning UPF, Red, Icon-plus-text Labels, Ultra-Processed, Yellow, Icon-plus-text Labels, Contains Food Additives, Yellow, Icon-plus-text Labels, Warning Ultra-Processed, Yellow, Icon-plus-text Labels, Warning UPF, Yellow, Icon-plus-text Labels, Ultra-Processed, Red, Text-only Labels, Contains Food Additives, Red, Text-only Labels, Warning Ultra-Processed, Red, Text-only Labels, Warning UPF, Red, Text-only Labels, Ultra-Processed, Yellow, Text-only Labels, Contains Food Additives, Yellow, Text-only Labels, Warning Ultra-Processed, Yellow, Text-only Labels, Warning UPF, Yellow, Text-only Labels
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
14,720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 27, 2026, 4:17 PM EDT
Completed Phase 2 Interventional Results available

Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP

NCT00220727
View directory record Official record
Conditions
Purpura, Thrombocytopenic, Idiopathic
Interventions
Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
12 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 27, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Study of Qualaquin and Midazolam

NCT00785486
View directory record Official record
Conditions
Healthy
Interventions
Midazolam Alone, Qualaquin (quinine) alone steady state, Midazolam and Qualaquin at steady state
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 31, 2012 · Synced Oct 27, 2026, 4:17 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Sex Differences in Myocardial Steatosis Induced Left Ventricular Dysfunction

NCT04671966
View directory record Official record
Conditions
Heart Diseases, Left Ventricular Dysfunction
Interventions
Estradiol patch, Cetrotide, Fasting, Lower Body Negative Pressure
Drug · Other
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
18 Years to 30 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 27, 2026, 4:17 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy

NCT03889756
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine infusion, Midazolam infusion
Drug
Lead sponsor
Yale University
Other
Eligibility
13 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 27, 2026, 4:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Short-term Effects of Caffeine and a Multi-ingredient Pre-workout on Exercise Performance

NCT07024940
View directory record Official record
Conditions
Coffee, Anthocyanins, Exercise Performance
Interventions
Ethiopian Coffee, Supplement, Water (Placebo)
Other · Dietary Supplement
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 27, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed-Fast Crossover Study to Assess the Effect of Food With CTx-1301 in Healthy Subjects

NCT04449250
View directory record Official record
Conditions
Healthy Volunteers in Fed and Fasted State
Interventions
Dexmethylphenidate
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 27, 2026, 4:17 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Transforming Maternal Mental Health Care

NCT07766174
View directory record Official record
Conditions
Perinatal Mental Health
Interventions
Lōvu platform, Standard Care Arm
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 27, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia

NCT02714569
View directory record Official record
Conditions
Dyslipidemias
Interventions
LY3202328, Placebo, Atorvastatin, Simvastatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
4
States / cities
Miami, Florida • Lenexa, Kansas • Marlton, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 27, 2026, 4:17 PM EDT
Completed Not applicable Interventional

Biomechanical and Neural Mechanisms of Post-stroke Gait Training

NCT04380454
View directory record Official record
Conditions
Stroke
Interventions
Functional electrical stimulation (FES), Fast treadmill walking
Device · Other
Lead sponsor
Emory University
Other
Eligibility
35 Years to 90 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 27, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of [¹⁴C]-LY3484356 in Healthy Female Participants

NCT04991766
View directory record Official record
Conditions
Healthy
Interventions
[¹⁴C]-LY3484356, LY3484356, [¹⁴C]-LY3484356 (IV)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 27, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

RDEA3170 PK/PD Study

NCT02608710
View directory record Official record
Conditions
Gout
Interventions
RDEA3170 4.5 mg, RDEA3170 6 mg, RDEA3170 12 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Oct 27, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects

NCT03451110
View directory record Official record
Conditions
Healthy Subjects
Interventions
lemborexant, Loestrin, famotidine, fluconazole
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 27, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Pharmacokinetics of Gefapixant (MK-7264) in Participants With Renal Insufficiency (MK-7264-026)

NCT03108924
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Gefapixant
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Hialeah, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 27, 2026, 4:17 PM EDT
Recruiting Not applicable Interventional

Improving Visual Field Deficits With Noninvasive Brain Stimulation

NCT05085210
View directory record Official record
Conditions
Visual Field Defect, Peripheral, Stroke, Visual Impairment, Hemianopsia, Quadrantanopia, Cortical Blindness, Visual Field Defect Homonymous Bilateral, Occipital Lobe Infarct, Visual Fields Hemianopsia
Interventions
transcranial random noise stimulation (tRNS), Computer Based Visual Training, Sham stimulation, Virtual Reality Based Visual Training
Device · Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 27, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Colchicine Tablets

NCT01021020
View directory record Official record
Conditions
Healthy
Interventions
Colchicine, Colchicine/Probenecid
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 9, 2009 · Synced Oct 27, 2026, 4:17 PM EDT
Completed Not applicable Interventional Results available

Performance Evaluation of the Lucira COVID-19 & Flu Test

NCT06141824
View directory record Official record
Conditions
COVID-19, Influenza
Interventions
Lucira COVID-19 & Flu Test
Device
Lead sponsor
Lucira Health Inc
Industry
Eligibility
2 Years and older
Enrollment
1,361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Cullman, Alabama • Colton, California • Oakland, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 27, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Venglustat in Patients With Renal Impairment

NCT03687554
View directory record Official record
Conditions
Healthy Volunteers, Polycystic Kidney, Autosomal Dominant
Interventions
Venglustat GZ/SAR402671
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 27, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of GC4419 in Healthy Adult Subjects

NCT03163173
View directory record Official record
Conditions
Healthy Volunteers, Healthy
Interventions
GC4419
Drug
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 27, 2026, 4:17 PM EDT
Completed Not applicable Interventional Results available

Fast Arm Motor Skill Training in Chronic Stroke Survivors

NCT05013762
View directory record Official record
Conditions
Cerebrovascular Stroke
Interventions
Fast intervention, Active Monitoring
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
21 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 27, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers

NCT06137703
View directory record Official record
Conditions
Biological Availability
Interventions
Zavegepant 100mg non-enteric coated soft gel capsule, Zavegepant 100mg immediate release tablet, Zavegepant 2 x 100mg immediate release tablets, Zavegepant 4 x 25mg enteric coated soft gel capsule
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 27, 2026, 4:17 PM EDT